Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean para live and somatotropin and sus scrofa pituitary gland?
Displaying drugs 926 - 950 of 14592 in total

Osimertinib

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Abemaciclib

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Ferric maltol

Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Matched Description: … bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and …
Matched Categories: … Blood and Blood Forming Organs …

Idelalisib

Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Description: … (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils ... signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and ... type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tovorafenib

Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational
Matched Description: … growth and survival. ... [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell ... [L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation …

Tezacaftor

Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … consequently abnormal fluid and ion transport across cell membranes. ... [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and …
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …

Ceftobiprole

Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug ceftobiprole medocaril. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA). The EMA's Committee for Medicinal Products for Human Use (CHMP)...
Approved
Investigational
Matched Description: … infections and bacteremia in April 2024. ... Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative ... was subsequently approved in the United States with additional indications for skin and skin structure …

Aripiprazole lauroxil

Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of aripiprazole, which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors . Affecting about 1% of the...
Approved
Investigational
Matched Description: … It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and ... catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of emotional ... patients are faced with social stigma and discriminations. …
Matched Categories: … Aripiprazole and prodrugs …

Copanlisib

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Description: … , that exists in different isoforms and is often overexpressed in hematological malignancies. ... pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and ... PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Benfotiamine

Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.
Approved
Experimental
Matched Description: … Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes …
Matched Categories: … Alimentary Tract and Metabolism …

Larotrectinib

Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Description: … plays an important role in tumor cell growth and survival. ... receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and ... Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Isoprenaline

Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising...
Approved
Investigational
Matched Description: … anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and ... [A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and ... found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and …
Matched Categories: … Adrenergic and Dopaminergic Agents ... isoprenaline and other drugs for obstructive airway diseases …

Doxacurium

Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Approved

Deferasirox

Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Approved
Investigational
Matched Description: … Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload …

Magnesium trisilicate

Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.
Approved
Matched Categories: … Aluminum and magnesium containing antacids …

1,2-Benzodiazepine

Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.
Approved
Investigational
Matched Description: … of Gallbladder, Biliary Tract and Pancrease. ... Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac ... Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …

Carprofen

Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild,...
Approved
Vet approved
Withdrawn
Matched Description: … nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory drugs. ... generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and …

Telithromycin

Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S...
Approved
Matched Description: … Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and ... Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation …
Matched Categories: … Erythromycin and similars ... Macrolides, Lincosamides and Streptogramins …

Certolizumab pegol

Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated...
Approved
Matched Description: … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated ... [A176606] Certolizumab does not require glycosylation for active function and hence, its production ... The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Lemborexant

Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Description: … receptors, lemborexant and other orexin antagonists (e.g. ... receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and ... potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and …
Matched Categories: … Hypnotics and Sedatives ... Sleep Initiation and Maintenance Disorders …

Alprazolam

Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse...
Approved
Illicit
Investigational
Matched Description: … ketoconazole and itraconazole. ... Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. ... [L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepines and benzodiazepine derivatives …

Flurazepam

A benzodiazepine derivative used mainly as a hypnotic.
Approved
Illicit
Investigational
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepines and benzodiazepine derivatives …

Sitaxentan

Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
Approved
Investigational
Withdrawn

Miglitol

Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start...
Approved
Matched Description: … amount of poly and oligosaccharides in the diet. ... Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the ... glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and …
Matched Categories: … Alimentary Tract and Metabolism …

Apraclonidine

Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.
Approved
Matched Categories: … Antiglaucoma Preparations and Miotics …
Displaying drugs 926 - 950 of 14592 in total